SCHEMBL389991

SCHEMBL389991

CC(C)(C)OC(=O)N1CCC(OCc2noc(-c3cc4c(C#N)nccc4o3)n2)CC1

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 15/20 0.47
CETP P11597 2/20 0.44
TBK1 Q9UHD2 2/20 0.38
NSD2 O96028 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL390095 0.91 GPR119 (0.45) GPR119CETPNSD2
SCHEMBL390002 0.89 GPR119 (0.47) GPR119CETPTBK1
SCHEMBL389716 0.89 GPR119 (0.48) GPR119CETPTBK1
SCHEMBL1069804 0.89 GPR119 (0.33) GPR119CETPTBK1
SCHEMBL9107919 0.89 CETP (0.38) GPR119CETP
SCHEMBL392191 0.88 GPR119 (0.47) GPR119CETPTBK1
SCHEMBL390006 0.88 GPR119 (0.47) GPR119CETPTBK1
SCHEMBL390062 0.88 GPR119 (0.47) GPR119CETPTBK1
SCHEMBL389862 0.87 GPR119 (0.46) GPR119CETPTBK1
SCHEMBL387449 0.86 GPR119 (0.45) GPR119CETPTBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193359-B2 G-protein coupled receptor agonists PROSIDION LIMITED (GB) 2012-06-05 US claimed
US-8193359-B2 G-protein coupled receptor agonists PROSIDION LIMITED (GB) 2012-06-05 US disclosed
US-8193359-B2 G-protein coupled receptor agonists PROSIDION LIMITED (GB) 2012-06-05 US disclosed
US-8193359-B2 G-protein coupled receptor agonists PROSIDION LIMITED (GB) 2012-06-05 US disclosed
US-8101626-B2 GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto ARENA PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-7816364-B2 GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto ARENA PHARMACEUTICALS, INC. (US) 2010-10-19 US disclosed
US-20100190750-A1 GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto ARENA PHARMACEUTICALS, INC. (US) 2010-07-29 US disclosed
US-20090099227-A1 G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-04-16 US disclosed
US-20090099227-A1 G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-04-16 US disclosed
US-20090099227-A1 G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190750-A1 GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto GPR119, GLP1R, GPR4 GPR119 1/4885CETP 1734/4885TBK1 2307/4885
US-20090099227-A1 G-Protein Coupled Receptor Agonists GPR119, GPR65, GPR84 GPR119 1/4885CETP 886/4885TBK1 2565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.